Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Acalabrutinib

Review the clinical trials studying acalabrutinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 25

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Status: Active
Location: 8 locations
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.
Status: Active
Location: 5 locations
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Status: Active
Location: 4 locations
Acalabrutinib with or without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: 3 locations
MRD Adapted Therapy with Venetoclax, Obinutuzumab, and Acalabrutinib for the Treatment of High- or Intermediate-Risk Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: 3 locations
Acalabrutinib for the Treatment of Recurrent or Refractory Central Nervous System Lymphoma
Status: Active
Location: 3 locations
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Status: Active
Location: 11 locations
Acalabrutinib Maintenance for the Treatment of Patients with Large B-cell Lymphoma
Status: Active
Location: 2 locations
Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax and Ibrutinib or Acalabrutinib in Treating Patients with High-Risk Chronic Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Acalabrutinib and Venetoclax with or without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Acalabrutinib in Combination with Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: 2 locations
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Modified Immune Cells (CD19 CAR T cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Status: Active
Location: See ClinicalTrials.gov
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Status: Active
Location: See ClinicalTrials.gov
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Status: Active
Location: 2 locations